હોમ › મલ્ટિપલ માયલોમા › જ્યોર્જિયા › Atlanta
Atlanta, GA માં મલ્ટિપલ માયલોમા ક્લિનિકલ ટ્રાયલ્સ
Atlanta (લગભગ 30 માઇલની અંદર) ની સાઇટ્સ પર મલ્ટિપલ માયલોમા માટે 41 અભ્યાસો ભાગીદારો શોધી રહ્યા છે. કોઈ અભ્યાસ ખોલો અને જુઓ કે કોઈ જોડાઈ શકે છે અને અભ્યાસ ટીમ સાથે સંપર્ક કેવી રીતે કરવો.
અધિકૃત અભ્યાસ ટેક્સ્ટ (અંગ્રેજી)
અહીં અભ્યાસ માટે ભરતી કરી રહ્યા છો? આ પેજની ટોચ પર તેને ફીચર કરો — 30 દિવસ માટે $99 →
A Study Comparing AZD0120, a Dual-targeted CAR-T Against B-cell Maturation Antigen (BCMA) and CD19, Versus Standard Regimens in Participants With Relapsed Refractory Multiple Myeloma (DURGA-4)
ભરતી ચાલુ છેફેઝ 3
- Research Site, Atlanta
A Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Daratumumab, and Dexamethasone Plus Pomalidomide in Multiple Myeloma
ભરતી ચાલુ છેફેઝ 1/2
- Emory University Winship Cancer Center, Atlanta
A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma
ભરતી ચાલુ છેફેઝ 3
- Emory University, Atlanta
A Phase I, Open-label, Multicenter Study to Evaluate the Safety, Tolerability, Cellular Kinetics, Immunogenicity, Pharmacodynamics, and Preliminary Efficacy of AZD0120 in Participants With Multiple Myeloma (DURGA-2)
ભરતી ચાલુ છેફેઝ 1
- Research Site, Atlanta
A Study of JNJ-79635322 in Combination With Daratumumab With or Without Lenalidomide for Multiple Myeloma, Newly Diagnosed AL Amyloidosis, and High-risk Smoldering Multiple Myeloma or JNJ-79635322 in Combination With Pomalidomide for Multiple Myeloma
ભરતી ચાલુ છેફેઝ 1
- Winship Cancer Institute Emory University, Atlanta
A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma
ભરતી ચાલુ છેફેઝ 3
- Emory University, Atlanta
A Study of Talquetamab in Participants With Relapsed or Refractory Multiple Myeloma
ભરતી ચાલુ છેફેઝ 2
- Emory University Winship Cancer Institute, Atlanta
A Study to Compare Linvoseltamab and Daratumumab Treatment in High-Risk Smoldering Multiple Myeloma (HR-SMM)
ભરતી ચાલુ છેફેઝ 3
- Emory University - Winship Cancer Institute, Atlanta
A Long-term Study for Participants Previously Treated With Ciltacabtagene Autoleucel
ભરતી ચાલુ છેફેઝ 4
- Emory University, Atlanta
A Study of mRNA-2808 in Participants With Relapsed or Refractory Multiple Myeloma
ભરતી ચાલુ છેફેઝ 1/2
- Emory University Hospital, Atlanta
A Study to Assess A Change in Disease Activity and Adverse Events of Intravenous Etentamig and Daratumumab (Etentamig+D) Compared to Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Adult Participants With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant
ભરતી ચાલુ છેફેઝ 2/3
- Winship Cancer Institute of Emory University /ID# 277667, Atlanta
TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer
ભરતી ચાલુ છેફેઝ 2
- Cancer Treatment Centers of America - Atlanta, Atlanta
- Emory University Winship Cancer Institute, Atlanta
Study to Assess Safety of HDP-101 in Patients With Relapsed Refractory Multiple Myeloma
ભરતી ચાલુ છેફેઝ 1/2
- Winship Cancer Institute of Emory University, Atlanta
Collection of Tissue Samples for Cancer Research
ભરતી ચાલુ છેઅવલોકનકારી અભ્યાસ
- Emory University, Atlanta
A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma (QUINTESSENTIAL-2)
ભરતી ચાલુ છેફેઝ 3
- Winship Cancer Institute, Emory University, Atlanta
Study of Arlocabtagene Autoleucel (BMS-986393) a GPRC5D-directed CAR T Cell Therapy in Adult Participants With Relapsed or Refractory Multiple Myeloma
ભરતી ચાલુ છેફેઝ 2
- Winship Cancer Institute of Emory University, Atlanta
- Northside Hospital, Atlanta
Cevostamab in Combination With Pomalidomide and Dexamethasone Versus Standard of Care in Participants With Previously Treated Multiple Myeloma
ભરતી ચાલુ છેફેઝ 3
- Emory University Hospital Midtown, Atlanta
Belantamab Mafodotin, Pomalidomide and Dexamethasone for the Treatment of High-Risk Myeloma
ભરતી ચાલુ છેફેઝ 2
- Emory University/Winship Cancer Institute, Atlanta
A Study to Evaluate a Novel Gene Therapy in Patients With Relapsed and Refractory Multiple Myeloma
ભરતી ચાલુ છેફેઝ 1
- Emory University Hospital, Atlanta
A Modular, Phase I/II, Multicentre Study to Evaluate AZD4045, in Participants With Relapsed or Refractory Multiple Myeloma
ભરતી ચાલુ છેફેઝ 1/2
- Research Site, Atlanta
AZD0305 as Monotherapy or in Combination With Anticancer Agents in Participants With Multiple Myeloma
ભરતી ચાલુ છેફેઝ 1/2
- Research Site, Atlanta
A Study of an MMSET Inhibitor in Patients With Relapsed and Refractory Multiple Myeloma
ભરતી ચાલુ છેફેઝ 1
- The Winship Cancer Institute of Emory University, Atlanta
AZD0120 in Relapsed/Refractory Multiple Myeloma (DURGA-1)
ભરતી ચાલુ છેફેઝ 1/2
- Research Site, Atlanta
Study of AZD0120 in Newly Diagnosed Multiple Myeloma Ineligible for ASCT
ભરતી ચાલુ છેફેઝ 3
- Research Site, Atlanta
A Study to Learn About the Effects of Cemsidomide in Combination With Elranatamab in Relapsed/Refractory Multiple Myeloma Subjects
ભરતી ચાલુ છેફેઝ 1
- Winship Cancer Institute, Emory University, Atlanta
A Study to Evaluate the Efficacy of Cemsidomide + Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma
ભરતી ચાલુ છેફેઝ 2
- Winship Cancer Institute, Emory University, Atlanta
Evaluating Premedication Regimens (Methylprednisolone vs Dexamethasone-based) for the Prevention of Systemic and Injection Site Reactions to Motixafortide in Patients With Multiple Myeloma Undergoing Stem Cell Mobilization, PARADE Trial
ભરતી ચાલુ છેફેઝ 4
- Emory University Hospital/Winship Cancer Institute, Atlanta
A Study to Assess Change in Disease Activity and Adverse Events (AE)s in Adult Participants With Multiple Myeloma Receiving T Cell Engaging Bi/Tri-specific Antibodies Intravenously (IV)/Subcutaneously (SC) Alone or in Combinations
ભરતી ચાલુ છેફેઝ 1/2
- Winship Cancer Institute of Emory University /ID# 274830, Atlanta
A Study to Evaluate the Safety, Effectiveness and Tolerable Dose of Arlocabtagene Autoleucel (BMS-986393) in Novel Combinations in Participants With Relapsed and/or Refractory Multiple Myeloma
ભરતી ચાલુ છેફેઝ 1
- Northside Hospital, Atlanta
A Study to Examine the Effects of Novel Therapy Linvoseltamab in Combination With Other Cancer Treatments for Adult Participants With Multiple Myeloma That is Resistant to Current Standard of Care Treatments
ભરતી ચાલુ છેફેઝ 1
- Winship Cancer Institute of Emory University, Atlanta
Study to Evaluate CCS1477 (Inobrodib) in Haematological Malignancies
ભરતી ચાલુ છેફેઝ 1/2
- Emory Winship Cancer Institute, Atlanta
Personalized Autologous Transplant for Multiple Myeloma
ભરતી ચાલુ છેફેઝ 1
- Winship Cancer Institute of Emory University, Atlanta
Low-Dose Radiotherapy in Treating Painful Bone Metastases in Patients With Multiple Myeloma
ભરતી ચાલુ છે
- Emory University Hospital/Winship Cancer Institute, Atlanta
Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation
ભરતી ચાલુ છેફેઝ 3
- Emory University Hospital, Atlanta
Study to Assess Safety and Tolerability of OPN-6602 in Subjects With Relapsed and/or Refractory Multiple Myeloma
ભરતી ચાલુ છેફેઝ 1
- Emory Winchip Cancer Center, Atlanta
A Study of Belantamab Mafodotin Administered in Combination With Lenalidomide and Dexamethasone (BRd) Versus Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Participants With Newly Diagnosed Multiple Myeloma (NDMM) Who Are Ineligible for Autologous Stem Cell Transplantation (TI-NDMM)
ભરતી ચાલુ છેફેઝ 3
- GSK Investigational Site, Atlanta
CAR T-cell Therapy in Patients With Renal Dysfunction
ભરતી ચાલુ છેફેઝ 2
- Caitlin Guzowski, Atlanta
Phase 1/2 Study of Linvoseltamab in Adult Patients With Relapsed or Refractory Multiple Myeloma
ભરતી ચાલુ છેફેઝ 1/2
- Emory University Hospital, Atlanta
Study of ISB 2001 in Relapsed/Refractory Multiple Myeloma (TRIgnite-1)
ભરતી ચાલુ છેફેઝ 1
- Winship Cancer Institute, Atlanta
IDP-023 as a Single Agent and in Combination With Antibody Therapies in Patients With Advanced Hematologic Cancers
ભરતી ચાલુ છેફેઝ 1/2
- Emory University Hospital, Atlanta
A Study to Evaluate the Safety, PK/PD of (OriCAR-017) in Subjects With RR/MM - RIGEL Study
ભરતી ચાલુ છેફેઝ 1
- Northside Hospital, Atlanta
અન્ય શહેરોમાં મલ્ટિપલ માયલોમા ટ્રાયલ્સ
- New York City, NY60 અભ્યાસો
- Boston, MA42 અભ્યાસો
- Houston, TX38 અભ્યાસો
- Durham, NC37 અભ્યાસો
- Nashville, TN32 અભ્યાસો
- Denver, CO27 અભ્યાસો
- Rochester, MN24 અભ્યાસો
- St. Louis, MO24 અભ્યાસો
- Columbus, OH24 અભ્યાસો
- Baldwin Park, CA23 અભ્યાસો
- Chicago, IL22 અભ્યાસો
- Seattle, WA22 અભ્યાસો
Atlanta માં અન્ય અભ્યાસો
- કેન્સર (બધા પ્રકાર)49 અભ્યાસો
- નોન-સ્મોલ સેલ લંગ કેન્સર47 અભ્યાસો
- સ્તન કેન્સર41 અભ્યાસો
- પ્રોસ્ટેટ કેન્સર33 અભ્યાસો
- એક્યુટ માયલોઇડ લ્યુકેમિયા30 અભ્યાસો
- ઓવેરિયન કેન્સર29 અભ્યાસો
- ફેફસાનું કેન્સર29 અભ્યાસો
- કોલોરેક્ટલ કેન્સર29 અભ્યાસો
- મેટાસ્ટેટિક કેન્સર28 અભ્યાસો
- હૃદય અપૂરતાપણું25 અભ્યાસો
- મેજર ડિપ્રેસિવ ડિસઓર્ડર25 અભ્યાસો
- માથું અને ગળાનો સ્ક્વેમસ સેલ કાર્સિનોમા24 અભ્યાસો
ClinicalTrials.gov પરથી, તારીખ 5 ઑક્ટો, 2026 ના ડેટા સાથે. દરેક અભ્યાસની પોતાની પાત્રતા શરતો હોય છે; અભ્યાસ ટીમ નક્કી કરે છે કે કોઈ જોડાઈ શકે છે કે નહીં.